The role of tumour-specific antigens (TSAs) as targets of anticancer immunity was first recognized in the last century, with studies of TSA-based vaccines becoming more prevalent in the past decade 1-3 (Box 1).
Neoantigens are defined here as a subset of TSAs generated by non-synonymous mutations and other genetic variations specific to the genome of a tumour, presented by major histocompatibility complex (MHC) molecules, and recognized by endogenous T cells. The most commonly studied class of neoantigens are those derived from singlenucleotide variants (SNVs), which cause non-synonymous changes in a protein that subsequently may trigger antigen-specific T cell responses against the tumour. These conventional neoantigens have the distinct advantage over other classes of tumour antigens (for example, tumour-associated antigens and cancer-testis antigens) of having no expression in normal tissues 4 . As a result, T cells with specificity for these neoantigens can escape negative selection in the thymus, leading to the generation of a TSA-specific T cell repertoire 5 . Despite the advantages of SNV neoantigens, their applicability as vaccine sources. Unlike SNV neoantigens, alternative TSAs are not necessarily restricted to protein-coding exons, allowing for a greater repertoire of available targets. Predicted tumour antigen burden has demonstrated that the expression of various classes of TSAs is not always correlated, with some SNV-low cancers containing high alternative-TSA expression. This is exemplified by clear-cell renal-cell carcinoma (ccRCC), an immune checkpoint inhibitor sensitive cancer that has a low predicted SNV burden but high expression of predicted frameshift neoantigens 10 and tumourspecific endogenous retroviral antigens 11 . Thus, studying these alternative TSAs may broaden the scope and increase the number of targets available to test in therapeutic vaccines and/or cellular therapies. Additionally, leukaemia and sarcoma (which are among the cancers with the lowest predicted SNV burden 12 ) express gene fusions 13, 14 and splice variant transcripts 15, 16 shared across multiple tumours, potentially allowing for universal off-the-shelf therapies.
In this Opinion article, we will characterize several major classes of alternative TSAs, including those generated from mutational frameshifts, splice variants, gene fusions, endogenous retroelements and other classes, such as human leukocyte antigen (HLA)-somatic mutation-derived antigens and post-translational TSAs ( Fig. 1 ; TaBle 1 ). One class of TSA not covered here is the viral-derived cancer antigens (for example, human papillomavirus (HPV) and Epstein-Barr virus (EBV)), which have been previously reviewed [17] [18] [19] [20] [21] . We will begin by providing a brief overview of TSA computational prediction and then discuss the biology, available computational tools, preclinical and/or clinical studies, and relevant cancers for each alternative TSA class. Finally, we will discuss the current challenges impeding therapeutic application of alternative TSAs and solutions to aid their clinical translation. In addition to a review of the literature, recent studies (including several from our group) have provided estimates of the antigenic burden of each TSA class among The Cancer Genome Atlas (TCGA) pan-cancer data (including selected tumour-specific viral antigens), which we have compiled here as a resource ( Fig. 2 and Supplementary Fig. 1 ; viral antigens targets may be limited to cancers with highly immunogenic neoantigens, likely a subset of the total neoantigen load for any given tumour. Metastatic melanoma (which contains the highest SNV burden of any cancer 6 ) has been the primary focus of initial neoantigen clinical studies 2, 3 , and in this tumour type, as in lung cancer, tumour mutational burden (which estimates neoantigen load) has been associated with the response to immune checkpoint inhibition 7 . One hypothesis for this association is the increased likelihood in these tumour types of neoantigen generation and T cells bearing neoantigenspecific T cell receptors (TCRs). However, the number of neoantigens required for driving a clinical response is unknown, and it has been shown that tumours with a low mutational burden can have neoantigen-specific T cell populations boosted by therapeutic personalized neoantigen vaccines 8, 9 . Many investigators, including our group, have begun to evaluate alternative TSAsdefined as high-specificity tumour antigens arising from non-SNV-containing genomic , OptiType 23 , PHLAT 24 , HLAScan 25 or HLAProfiler 26 ), which relies on DNA and/or RNA-seq data, depending upon the platform. Peptide enumeration is then performed, whereby variant genomic regions are translated into peptide sequences, with removal of translation-incompatible sequences such as nonsense mutations. Following this, HLA binding prediction is performed using prediction software (for example, NetMHCpan 27 ), with higheraffinity peptides being characterized by either ranked percentiles or K D values of ≤500 nM (the commonly accepted binding affinity cutoff in the field) 3, 27, 28 . The majority of MHC binding affinity prediction tools rely on machine-learning algorithms (including artificial neural networks) trained on validated epitope reference databases, where peptide binding to MHC molecules has been measured using biochemical assays 29, 30 . Finally, the predicted TSAs are used to generate a therapeutic product, either as a vaccine (that is, a DNA or RNA, peptide or dendritic cell vaccine) or a cellular therapy product (that is, adoptive T cell therapy). Below, we will discuss the biology of each alternative TSA class, with detailed descriptions of the available computational prediction tools. 10, 31 . Epitopes generated from these mutations could induce a T cell response similar to SNV neoantigens, due to decreased potential for negative selection in the thymus against the INDEL neoantigen-specific T cell.
Mutational frameshift neoantigens
Cancer types that are particularly relevant for targeting INDEL neoantigens include microsatellite instability-high (MSI-H) tumours, as well as all renal cell carcinomas (RCCs). Early studies examining the role of INDEL mutations for antitumour immunity were mainly pursued in colon cancer, where MSI caused by hereditary diseases (for example, lynch syndrome) and in sporadic tumours (MSI-H in 15%) is common 32, 33 . MSI-H tumours are also observed in other non-hereditary cancers, including gastric, endometrial and pancreatic cancers 34 . MSI-H cancers are characterized by impaired DNA mismatch repair pathways and are associated with significantly greater INDEL burden than non-MSI-H tumours 31, 35 . The association between INDEL burden and the presence of tumour-infiltrating T cells has been well described in the literature, providing early support for the hypothesis that MSI-H tumours would be susceptible to immunotherapies 31, [36] [37] [38] [39] . www.nature.com/nrc P e r s P e c t i v e s
Box 1 | Historical context of neoantigen-based therapeutic vaccines
The identification of single-nucleotide variant (SNv) neoantigens as targets of antitumour immunity was an important initial step for the understanding of tumour-specific antigen (TSA) vaccine therapies. This process began with the theorization that SNv neoantigens could be leveraged to develop therapeutic vaccines and cellular modalities 5, 195 . Subsequently, proof of concept for SNv neoantigen therapeutic vaccines was demonstrated in preclinical tumour models, providing the framework for neoantigen clinical trials:
• The identification and description of non-synonymous somatic point mutations in mouse models produce candidate targets 196 • Tumour neoantigens function as targets of T cells activated by immune checkpoint inhibitor therapy 197 • A combined exome and mass spectrometry approach identifies neoantigens 191 • Characterization of mouse tumour neoantigens demonstrates that the majority of recognition is provided by CD4 + T cells 176 more recently, human neoantigen therapy trials have been pursued in the contexts of:
• Dendritic cell 198 , peptide 3 and DNA 2 neoantigen vaccines in melanoma
• Neoantigen vaccines in low-mutation-containing glioblastoma 8, 9 prediction along with integration of a publicly available variant caller (for example, Indelocator and Strelka
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) and peptide-MHC binding prediction methods). Among these tools, Neopepsee is unique in its integration of machine-learning algorithms to predict immunogenicity -as well as peptide-MHC binding -a feature not easily validated biologically in human neoantigen studies before the induction of therapy. [52] [53] [54] [55] [56] [57] , intron retention [58] [59] [60] [61] [62] [63] or dysregulation of the spliceosome machinery in the tumour cell 15, 64, 65 . Other types of post-transcriptionally derived TSAs include alternative ribosomal products (for example, ribosomal frameshifting 66, 67 , non-canonical initiation [68] [69] [70] [71] , termination codon read-through 69 , reverse-stand transcription 72 and doublet decoding 73 ) and post-translational splicing [74] [75] [76] -these two mechanisms are difficult to apply in anticancer therapies, given the lack of tools for predicting such products.
Translation of INDEL
The study of splice variant proteins has historically focused on haematological malignancies, with splice variant protein expression being understudied in solid tumours. As such, putative splice variant Mutations and other tumour-specific nucleotide sequences (shown in red) can be observed at the genomic DNA level, where they undergo transcription (1) and splicing to form mRNA (2) . Alternative splicing can occur at this step, to form splice variant mRNA. Next, translation occurs on variant mRNA , resulting in the production of variant proteins (3). Post-transcriptional frameshifts (for example, ribosomal slippage, among other mechanisms) can occur at this step, resulting in frameshifted protein variants. These proteins can then undergo proteasomal degradation (4) and transport to the endoplasmic reticulum (ER), to subsequently be loaded on major histocompatibility complexes (MHCs) (5) . Other forms of post-translational frameshift can occur during these steps (for example, protein splicing). Finally , peptides containing variant sequences can be presented at the cell surface in the context of MHC, resulting in T cell targetable tumour-specific antigens (6) . Chr, chromosome; ERV, endogenous retrovirus; INDEL , insertion or deletion; SNV, single-nucleotide variant.
antigens derived from these proteins have received less attention in solid tumours, with expression only recently validated 77 . In haematological cancers in which SNV burden is relatively low 6 , splice variant antigens could broaden the number of available TSA targets for therapeutic application. Splice variant proteins can arise through cis-acting mutations that disrupt or create splice site motifs or through transacting alterations in slicing factors that have historically been identified in haematological malignancies 77, 78 . The role of spliceosome machinery in the generation of splice variants in haematological malignancies is a current area of investigation. Mutations in spliceosome proteins (for example, splicing factor 3b subunit 1 (SF3B1), serine-and arginine-rich splicing factor 2 (SRSF2), U2 small nuclear RNA auxiliary factor 1 (U2AF1) and U2AF2) are common in myelodysplastic syndrome, acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and chronic lymphocytic leukaemia (CLL) [79] [80] [81] [82] [83] . Sharing of these spliceosome protein mutations across haematological cancer types has led to the hypothesis that spliceosome dysregulation may cause the expression of splice variant mRNAs, which are not detectable in normal tissues, leading to the translation of TSAs [84] [85] [86] . Beyond haematological malignancies, recent reanalysis of the TCGA pan-cancer dataset demonstrated a strong association between somatic mutations in components of the spliceosome machinery and the expression of splice variant products 77 , providing evidence for the relevance of splice variant antigens in solid tumours. . Many of these tools (for example, SpliceGrapher, SplAdder and ASGAL) predict alternative splicing events through the generation of splicing graphs. This splicing graph is generated through comparisons of spliced alignments of RNA-seq reads against a genome reference, which consists of vertices (nodes) that represent predicted splicing sites for a given gene as well as edges that represent exons and introns between splicing sites. In addition to these splice variant callers, at least one peerreviewed tool, Epidisco 46 (the computational pipeline for the multi-institutional PGV-001 personalized vaccine trial 94 ), has been described with the capacity to predict for splice variant antigens.
Jayasinghe et al. 52 reported MiSplice, which integrates DNA-seq and RNA-seq data in order to discover mutation-induced splice sites, which they applied to the TCGA pan-cancer dataset. Splice variant mutations contained 2-2.5x more predicted TSA candidates than did SNVs, with some tumorigenesis-related genes containing ≥40 unique predicted TSAs. Furthermore, predicted splice variant antigen burden was correlated with programmed cell death 1 ligand 1 (PDL1) expression, suggesting that PDL1 blockade therapy may be efficacious in tumours with a high frequency of splice variant antigens. Additionally, Kahles et al. 77 reported a comprehensive analysis of splice variants in the TCGA pan-cancer dataset and then used mass spectrometry to identify tryptic-digested polypeptides that contained splice variant antigens in 63 primary breast and ovarian cancer samples. This method found, on average, 1.7 predicted splice variant antigens per sample, with up to 30% more alternative splicing events in tumours than in normal tissues. Notably, Kahles et al. 77 also reported several known (SF3B1 and U2AF1) and novel (transcriptional adaptor 1 (TADA1), serine-threonine protein phosphatase PPP2R1A and isocitrate dehydrogenase 1 (IDH1)) splicing quantitative trait loci that were associated with alternative splicing events in 385 genes, suggesting that these loci are important for predicting the burden of splice variant antigens.
While these studies have demonstrated TSAs derived from cancer-specific splice junctions, further work will be needed to refine the computational methods for splice variant antigen prediction. Particular emphasis is needed on identifying novel splice junctions that are likely to yield mRNA isoforms that will not undergo nonsense-mediated decay 95 .
To address this problem, improved full-length mRNA isoform inference procedures or hybrid (that is, long-and short-read) RNA-seq algorithms will need to be developed. These procedures would identify the full-length splice variant transcript, allowing for filtering of transcripts that do not contain premature stop codons that could subsequently trigger nonsense-mediated decay.
While tumour-specific splice variants of particular genes have been described in multiple tumour types, there are currently no reports of the use of splice variant antigens in personalized therapies. For example, the presence of tumour-associated splice variants has been described in select genes, including receptor for hyaluronanmediated motility (RHAMM; two tumourenriched variants, RHAMM-48 and RHAMM-147 in multiple myeloma) 96 and Wilms tumour protein 1 (WT1; one variant, E 5+ , enriched in multiple cancers) [97] [98] [99] . WT1-derived peptides have been studied as a therapeutic target in leukaemias [100] [101] [102] [103] [104] and in lung 105 and kidney cancers 106 ; however, these trials did not use epitopes specific for the E 5+ splice variant. Additionally, an HLA-B44-restricted epitope derived from a variant of the minor histocompatibility antigen HMSD (HMSD-v) selectively expressed by primary haematological malignant cells (including those of myeloid lineage as well as multiple myeloma), but also by normal mature dendritic cells, was observed to be targeted by the CD8 + cytotoxic T cell clone 2A12-CTL 107 . Co-incubation of 2A12-CTL with primary AML cells conferred tumour resistance to immunodeficient mice after injection, suggesting that this HMSD-v derived antigen is a viable target for immunotherapy. Finally, Vauchy et al. 108 described a CD20 splice variant (D393-CD20) whose expression is detectable in transformed B cells and upregulated in various B cell lymphomas. They subsequently demonstrated the capacity of D393-CD20-derived epitope vaccines to trigger both CD4 + and CD8 + T cell responses in HLA-humanized transgenic mice, supporting the use of CD20 splice variant epitopes for targeted immunotherapies in B cell malignancies.
Gene fusion neoantigens
Gene fusion occurrence in cancer. Gene fusions were originally identified in leukaemia 109 , with subsequent observations in bladder 110 , breast 111 , renal 112 , colon 113 and lung cancers 114 (among others). Similar to splice variants, gene fusion proteins have been a focus of study in leukaemia (particularly AML, acute lymphocytic leukaemia (ALL), and chronic myeloid leukaemia (CML) 115 ) but also , where the INDEL-to-SNV ratio is significantly higher than in other cancer types (ccRCC, 0.85, and papillary RCC, 0.90; all others, 0.43 -0.72). Analysis of splice variant antigens has demonstrated a burden similar to that of INDEL neoantigens, with significant correlations with both INDEL and SNV neoantigen burden. A notable outlier is thyroid cancer (thyroid carcinoma (THCA)), where the average number of splice variant antigens per sample is higher than that of SNV neoantigens. The mean burden of fusion-derived neoantigens is highest in sarcomas (for example, sarcoma (SARC), 1.1; uterine carcinosarcoma (UCS), 0.78), with the carcinoma fusion burden being highest in breast (breast invasive carcinoma (BRCA), 0.70) and prostate (prostate adenocarcinoma (PRAD), 0.58) cancer. Testicular cancer (testicular germ cell tumour (TGCT)) has a substantially greater burden of human endogenous retrovirus (hERV)-derived tumour-specific antigens (TSAs) than any other TCGA cancer type. SNV and INDEL epitopes are derived from Thorsson et al. 12 . Fusion epitopes are derived from Gao et al.
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. Splice variant epitopes are derived from Jayasinghe et al. 52 . The viral epitopes are derived from Selitsky et al. 200 ; the hERV epitopes are derived from differentially expressed hERVs (>10-fold tumour-versus-mean normal expression by DESeq2) in Smith et al.
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; all TSA classes represent the average numbers of predicted class I human leukocyte antigen (HL A) binders (8-11 mers, <500 nM) predicted from NetMHCPan. Stomach adenocarcinoma (STAD) INDEL and SNV calls were absent from Thorsson et al. 12 , and oesophageal carcinoma, acute myeloid leukaemia and ovarian serous cystadenocarcinoma were not included in all original reports and so are absent from the figure. The data shown represent reanalysis of the above reports, with modification of the data to derive values comparable across TSA groups. ACC, adrenocortical carcinoma; BLCA , bladder urothelial carcinoma; CESC, cervical and endocervical cancers; CHOL , cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B cell lymphoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; LGG, brain lower-grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; PAAD, pancreatic adenocarcinoma; PCPG, phaeochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. A version of these data with individual numbers of unique TSAs by cancer type is available online (Supplementary Fig. 1 ). 121 , all of which may contribute to immune escape. As such, targeting of a single driver mutation may limit long-term therapeutic efficacy, whereby therapyresistant sub-clones with differential driver mutations and HLA expression profiles may arise. Although overall gene fusion frequency is relatively low compared to SNV and INDEL mutations, they can be shared within and between different tumour types 122 , making them identifiable through targeted methods (for example, fluorescence in situ hybridization) and potentially targetable by universal (as opposed to patient-specific) neoantigen-based strategies.
Prediction tools for gene fusion neoantigens.
Using current genomic techniques, gene fusions are typically identified through the alignment of fusion-containing reads from RNA-seq to more than one reference gene. In addition to general gene fusion callers 123 , several personalized gene fusion neoantigen-calling pipelines have been developed, including INTEGRATE-neo, which is specifically designed for the prediction of gene fusion neoantigens 124 . Using INTEGRATE-neo for analysis of the TCGA prostate adenocarcinoma cohort, 1,761 gene fusions were identified in 333 patient samples that generated 2,707 fusion transcript isoforms. Among this set, 61 (3.5% of the total) gene fusions were identified in >1 patient. Furthermore, 1,600 fusion junction peptides were identified from the 2,707 transcripts, of which 240 (15%) were predicted HLA binders 124 . Notably, the binding affinity scores for these 240 predicted neoantigens were skewed toward tighter affinity, suggesting that predicted fusion-derived neoantigens might have substantially better MHC binding capacity than SNV neoantigens. In addition to INTEGRATE-neo, several other tools have been described for gene fusion neoantigen calling, including pVACfuse (which performs neoantigen epitope calling using fusion variants reported from INTEGRATE-neo), NeoepitopePred 125 , Antigen.garnish 47 . Another trial, summarized in a publication from Mackall et al. 128 , studied the effects of dendritic cells pulsed with tumour-specific translocation breakpoints and E7, a peptide known to bind to HLA-A2 (given alongside autologous T cells +/-IL-2 and, serving as a control, influenza vaccinations) in patients with Ewing sarcoma and alveolar rhabdomyosarcoma. Compared with the 31% five-year overall survival in patients who underwent control apheresis, immunotherapy-treated patients had 43% five-year overall survival with minimal toxicity. These studies (among others 129, 130 ) underscore the potential for gene fusion neoantigens as universal offthe-shelf therapeutics, although their current clinical efficacy remains modest. This may be related in part to therapies only targeting a single gene fusion epitope, allowing for resistant sub-clones to arise in the later disease course 119, 120 . While an off-the-shelf approach has clear logistical merit, the identification and application of multiple Other filtering criteria may be performed after this step, such as immunogenicity prediction or filtering away sequences with high homology to self-antigens. e | Finally , therapies are generated using predicted tumour-specific antigens. These can be DNA , RNA or peptide vaccines or cellular therapies such as adoptive T cell therapy.
patient-specific gene fusion epitopes may improve therapeutic efficacy. Currently, few studies have applied patient-specific fusion proteins predicted through DNA-and/or RNA-seq methods for therapeutic vaccination. One recent example from Yang et al. 131 demonstrated the capacity of INTEGRATE-neo-derived fusion epitopes from head and neck cancers, including fusion epitopes derived from cancers with low overall mutational burden, to generate ex vivo activation of host and healthy donor T cells. Large-cohort clinical studies (for example, PGV-001 (reFs 46, 94 )) are currently underway that will include gene fusion neoantigens among the set of targeted TSAs. Future use of this potential class of neoantigens, alone or in combination, will require larger clinical trials with more robust clinical and immunological endpoints.
Endogenous retroelement antigens
Retrotransposons in cancer. retrotransposons are mobile genetic elements capable of self-replication through transcription and reverse transcription from genomic DNA 132 . They can be broadly divided into long-terminal repeat (LTR, also known as retroviral-like) and non-LTR subclasses, which differ in their genomic structures and replication mechanisms 132 .
Retrotransposons can be expressed in cancer through epigenetic dysregulation, either through inherently low methylation states 11, 133, 134 or following pharmacological induction of demethylation [135] [136] [137] [138] , resulting in transcription (and potential translation) of retroviral TSAs 139 . Among the many classes of retrotransposons, long interspersed nuclear elements (LINEs, a class of non-LTR retrotransposon) have been best characterized in terms of their ability to impact cancer biology. LINE-1 has been shown to induce cancer cell apoptosis 140 , trigger adenomatous polyposis coli (APC)-mediated tumorigenesis in colon cancer 141 and associate with clinical features and changes in cellular morphology in breast cancer 142, 143 , among other roles.
Endogenous retroviruses (ERVs), a type of LTR retrotransposon in mammals, are remnants of exogenous retroviruses that have been incorporated into the genome throughout evolution 144 . Human ERVs (hERVs) impact the pathogenesis and progression of cancers, including melanoma, lymphoma, leukaemia and ovarian, prostate, urothelial and renal carcinomas 134, [145] [146] [147] [148] [149] [150] [151] [152] [153] . Transcription of tumour-specific or enriched hERVs arises through epigenetic dysregulation of the cancer genome (which can be either inherent to the epigenetic state of the cancer or pharmacologically induced through epigenetic modulating agents), resulting in the expression of hERV-containing genomic regions otherwise not observed under physiological conditions 136, 138 . These tumour-specific or enriched hERVs can impact both the innate and adaptive immune system through distinct mechanisms. With the innate immune system, hERVs signal through innate sensors, most commonly the RIG-I-like pathway recognition of viral double-stranded RNAs 136, 138 . This results in downstream nuclear factor-κB (NF-κB)-mediated inflammation, with release of type I interferon, which causes immune activation and the expression of class I MHCs on tumour cells. Additionally, hERV-derived protein antigens can induce B cell and T cell activation [154] [155] [156] . Therefore, it has been proposed that tumour-specific hERV antigens could be applied to antitumour adoptive cellular therapies and therapeutic vaccines.
In addition to INDEL-derived neoantigens, hERVs have been proposed as key drivers of antitumour immunity in ccRCC 11, 157 . In ccRCC, hERVs demonstrate baseline expression in the tumour without exogenous pharmacological epigenetic modulation, with expression of these hERVs showing strong association with both clinical prognosis and response to immunotherapy 11, 157 . A 2015 study from Rooney et al. 158 provided an initial genomic evaluation into the interaction between hERVs and the tumour immune microenvironment, demonstrating three of 66 hERVs (ERVH-5, ERVH48-1, ERVE-4; identified in a previous study from Mayer et al. 159 ) to have tumour-specific expression and correlate with a cytotoxicity signature (granzyme A and perforin-1) in several cancers. On the basis of this study as well as several other translational studies showing the presence of an hERV-specific T cell response in ccRCC 155, 160 , our group performed comprehensive analyses into the role of hERVs in ccRCC 11, 157 . From immunogenomic analysis of hERVs in ccRCC, we demonstrated hERV-derived signatures to be the best predictor of patient prognosis, outperforming both clinical stage and M1-M4 molecular subtyping 11 . Additionally, the expression of tumour-specific hERV 4700 in pretreatment ccRCC samples was strongly associated with post-treatment response rates to anti-programmed cell death 1 (PD1) therapy. As such, hERV-derived antigens may be a viable alternative TSA target in ccRCC. Additionally, recent evidence suggests a potential role for hERVs in the modulation of low-grade glioma (where SNV burden is among the lowest of any cancer) 11 and testicular cancer (particularly those with KIT mutations), in which global DNA hypomethylation is associated with high hERV expression 133 .
Computational methods for the quantification of retroelement expression. Several computational methods for retroelement quantification currently exist, with the majority providing quantification of ERV-like or retrotransposon-like elements (partial or full-length) rather than fulllength, intact ERVs at specific genomic coordinates. This is due to the historic lack of well-annotated ERV references containing full proviral sequences and coordinates (rather than segments of ERV-like elements), which have only recently been published, to allow for mapping of full-length, intact ERVs 161, 162 . The most well-known tool is RepeatMasker, designed to identify interspersed repeats and low-complexity sequences of any class, including simple and tandem repeats, segmental duplications, and interspersed repeats (including ERVlike elements, LINEs and short interspersed nuclear elements (SINEs), LTRs and other classes) 163 . RepeatMasker used in its default state is not optimal for the detection of ERVs. However, many ERV-specific databases (for example, HERVd 164 , HESAS 165 and EnHERV 166 ) have subsequently been generated using RepeatMasker. A more recent quantifier designed by our group, aimed specifically for the analysis of hERVs from RNA-seq data, is hervQuant 11 , which quantifies full-length, intact hERV proviral sequences. The hervQuant reference is derived from Vargiu et al. 161 , which compiled genomic coordinates for 3,173 full-length hERV proviruses. Notably, hervQuant provided the first description of a broad genomic screening method for tumour-specific hERV antigens.
Because no tools are currently available to identify retroelement TSAs, the retroelement or ERV quantifiers described above must be paired with downstream epitope prediction software (for example, NetMHCpan 27 ) for retroelement antigen binding predictions. Additionally, because retroelements are present in the genome of both tumour and normal tissues, the prediction of tumour-specific retroelements provides unique challenges. Unlike the identification of neoantigens, retroelement TSAs must be derived through differential expression analysis of tumour versus normal-tissue RNA-seq. While hERVs and other retroelements share common homology among their overall sequences, which might theoretically make them unsuitable targets for TSA therapeutic approaches, they also exhibit highly unique regions specific to each hERV, capable of generating equally unique peptide epitopes 11 . Our analysis of hERV homology during the design of hervQuant revealed that only a minority of hERVs contain >95% sequence homology with one or more other hERVs, providing the basis for our ability to differentiate hERVs from short-read RNAseq data. Such hERV unique regions can be leveraged for hERV-based TSA therapies, as long as one can confirm the specificity of expression of that particular hERV within a tumour. Additionally, evidence of hERV-specific T cells found natively within the tumour immune microenvironment (for example, hERV 4700 (reF.
11 ) and CT RCC HERV-E 167 ) suggests a lack of thymic central tolerance against these hERV-specific epitopes.
Translational relevance of tumourspecific hERV targets. Several studies have described the translational application of tumour-specific hERV targets. A 2016 study from Cherkasova et al. 155 identified a CD8 + T cell clone from a patient with regressing ccRCC and found the clone to have tumour-specific cytotoxicity in vitro. The CTL recognized an antigen from a specific hERV, CT RCC HERV-E -which was the same as one of the tumourspecific hERVs (ERVE-4) described by Rooney et al. 158 and was also identified during our screen of differentially expressed hERVs in ccRCC (hERV 2256). This particular CTL clone is being studied in clinical trials for adoptive T cell therapy in metastatic ccRCC 167 . Our analysis also identified a second hERV (hERV 4700) with preferential expression in ccRCC compared to normal tissues, evidence of translation, and the presence of tumour-infiltrating CTLs specific for hERV-4700 gag-and pol-derived antigens of the virus 11 .
Other alternative TSAs HLA somatic mutation-derived neoantigens. Several studies have described somatic mutations in tumour HLAs that allow for altered T cell recognition. This was first described by Brandle et al. 168 , where mutated HLA-A2*0201 in a ccRCC tumour promoted an antitumour T cell response. This study did not elucidate whether the mechanism for T cell response was a result of TCR recognition of the antigen presented by the mutated HLA or whether the recognition was against the HLA molecule itself. Huang et al. 169 later demonstrated a similar finding in metastatic melanoma, with evidence that tumour-specific T cells may recognize an unknown antigen or set of antigens presented on mutated tumour HLA-A11. Together, these studies provided early evidence for potential targeting of novel antigens with specificity of binding to somatically mutated HLA on the tumour. A recent publication from Shulka et al. 22 presented whole-exome-based HLA-typing software, POLYSOLVER, that is able to call HLA somatic mutations with high prediction power, validated by RNA-seq (estimated sensitivity 94.1%, specificity 53.3%). More recently, HLAProfiler improved upon the breadth and accuracy of HLA somatic mutation calls and is able to work from RNA-seq data alone 26 . Combined with existing tools capable of predicting antigen binding directly from HLA sequences (for example, NetMHCpan), it is possible to predict for sets of antigens with specificity for the mutated tumour HLA, and thus specificity for antitumour T cell responses. Notably, a more advanced version of NetMHCpan is theoretically able to predict MHC binding to novel MHC molecules (including those containing mutations) through machinelearning prediction of MHC binding based on the amino acid sequence of the MHC variant 27 .
Post-translational TSAs. TSAs can arise post-translationally in tumours, with the potential to be targets for therapy, but they are difficult to predict with current computational tools. Post-translational splicing may occur in human cancers, resulting in the excision of a polypeptide segment followed by subsequent ligation of the free carboxyl-terminal with the aminoterminal of a new peptide 74, 75 . Additionally, a second class of antigens, known as T cell epitopes associated with impaired peptide processing (TEIPP), has been described as being presented on transporter involved in antigen processing (TAP)-deficient, MHClow tumours and as being recognized by a TEIPP-specific T cell population [170] [171] [172] [173] [174] . Interestingly, these epitopes are nonmutated and derived from housekeeping genes. Yet they are not presented on normal cells. TEIPP-specific T cells can escape thymic selection in wild-type mice (but not in TAP1-deficient mice), making them promising candidates for antitumour therapeutic targets.
Challenges and future directions Among the challenges impeding broad clinical application of alternative TSAs as therapeutics is the need to increase the sensitivity and accuracy of epitope prediction. The computational methods described above have provided avenues to predict a greater number of TSAs from a broader variety of genomic sources. However, methods both upstream and downstream of these algorithms can generally be applied to improve the prediction performance for all TSA classes. Here, we highlight several strategies that may universally increase the number and accuracy of all TSA predictions: improvement of MHC epitope binding predictions, algorithms for the direct prediction of TSA generation and immunogenicity, and mass spectrometry approaches to improve TSA calling accuracy.
MHC epitope calling.
Most TSA therapeutic vaccine studies to date have focused on the use of predicted MHC I binding epitopes, largely due to the classical hypothesis that CD8 + T cells play a greater role in antitumour immunity than do CD4 + T cells, as well as the better performance of MHC I epitope prediction algorithms than of MHC II epitope predictors. Despite this, further improvements will be required for both MHC I and II prediction algorithms to identify greater numbers of accurately predicted TSAs. A recent analysis from our group demonstrated that the accuracy of MHC I binding affinity predictions by NetMHCpan varied greatly by allele type, with performance measures being strongly correlated with the proportion of training data epitopes that were 'binders' (K D ≤ 500 nM, the generally accepted cut-off within the field for MHC binding), and less so with the amount of total training data per allele 175 . As such, alleles with fewer 'binders' in the training set suffered from poor sensitivity and specificity, suggesting that more high-quality data will be necessary for the application of MHC I predictors for clinical TSA prediction.
Regarding MHC II predictions, recent preclinical and clinical studies have suggested the importance of MHC II binding neoantigens in promoting antitumour immunity. A study from Kreiter et al. 176 was the first to describe MHC I-predicted neoantigens in fact being presented on MHC II, subsequently triggering CD4 + T cell responses. The relevance of SNV-specific CD4 + T cells in antitumour immunity is further supported by an earlier study from Tran et al. 177 , whereby infusion of an ERBB2 first described NN-align, which provided MHC II binding predictions trained on both the peptide-core and flanking-region characteristics, which significantly improved MHC II binding prediction performance. Although the binding affinity of an epitope is primarily determined by its peptide core, flanking-region characteristics can also influence the binding affinity. NN-align was later adapted as the core algorithm for NetMHCIIpan by Andreatta et al. 180 , which further improved performance, and led to the description of alternative epitope-MHC interactions. Even with these improvements to MHC II binding prediction, the performance characteristics of state-of-theart algorithms still lag behind MHC I binding predictors. While the importance of MHC II epitopes in promoting antitumour immunity has primarily been observed with SNV neoantigens, it is expected that alternative TSAs would similarly be applicable as MHC II epitopes. As such, increasing both the breadth of available TSAs from alternative sources and the improvements to MHC II epitope prediction can together provide a concerted strategy to multiplicatively increase the targetable pool of tumour antigens. www.nature.com/nrc P e r s P e c t i v e s
Glossary Apheresis
Medical technique used to purify various components of whole blood. apheresis can be performed to harvest purified T lymphocytes for subsequent immunotherapeutic application.
Artificial neural networks
a class of computational modelling based on biological neural networks, able to implement change based on training input and output information to form an optimized prediction model.
Binding core
The segment of polypeptide on an antigenic peptide responsible for interaction with the major histocompatibility complex binding groove. The binding core is recognized as an important predictor for binding affinity, but binding is also influenced by other factors of the epitope sequence.
Cancer-testis antigens
antigens whose expression is limited to cancer cells and reproductive tissues but not adult somatic tissue.
Cytogenic response
a decrease in the number of cells with a particular chromosomal trait (classically associated with the BCr-aBl gene fusion) in response to therapy.
Doublet decoding
Translational process by which an amino acid is translated from a two-base-pair codon rather than the conventional three-base-pair codon. This process can result in -1 frameshifting during translation.
Epitope specific portion of the antigen specifically recognized by a T or B cell receptor.
HLA typing
Process for identifying the Hla receptor allele of a particular tissue. This can be performed through a variety of molecular or immunological techniques.
Immunogenomic analysis study of the combined genomics of the cancer cell and immune cell components of a tumour.
Insertion or deletion
(iNDel). insertion of bases into or deletion of them from the genome of an organism, typically in the context of a mutation or genetic variation.
K D
Dissociation constant that measures the concentration of a ligand necessary to reversibly bind half of its corresponding molecular pair. in the context of peptidemajor histocompatibility complex (MHC) binding, this refers to the concentration of peptide necessary to bind half of all MHC molecules.
Lynch syndrome also known as hereditary nonpolyposis colorectal cancer. an autosomal-dominant genetic disorder of DNa mismatch repair, resulting in increased risk of microsatellite instability-driven colon cancer (among other cancer types).
Myelodysplastic syndrome a class of low-grade malignancies in which abnormal bone marrow stem cells fail to fully mature.
Negative selection
Process by which self-reactive T lymphocytes are deleted during T cell education in the thymus.
Neoantigens
antigens specific to the genome of the cancer cell.
Nonsense-mediated decay
Checkpoint by which mrNa transcripts containing premature stop codons are eliminated in order to reduce aberrant translation.
Post-translational splicing
Post-translational excision of polypeptides, with subsequent ligation of the carboxy-and amino-terminal residues.
Predicted neoantigens
genomically predicted neoantigens with unconfirmed tumour expression and/or in vivo immunogenicity.
Quantitative trait loci sections of DNa (loci) that are correlated with particular qualitative traits (or phenotypes) in an organismal population.
Retroelements
genetic elements capable of self-amplification, found within the genome of eukaryotic organisms. retrotransposon DNa can be transcribed into rNa, converted back into identical DNa via reverse transcription, and then inserted into the genome at particular target sites. retroelements include retrotransposons and endogenous retroviruses.
Retrotransposons a subset of retroelement in eukaryotic cells that possesses some characteristics of retroviruses and transposes through an rNa intermediary.
Ribosomal frameshifting
Process by which codons are translated in an out-of-frame manner via slippage of the ribosome into a +/-1 or 2 base-pair position.
Segmental duplications
long segments of repeated DNa (1-400 kb) with highly conserved sequences (>90%) that exist in the genome as a result of duplication events.
Spliceosome
Molecular machinery responsible for removal (splicing) of introns from pre-mrNa.
Tandem mass spectrometry
Multiple-step mass spectrometry (Ms), whereby the sample is first ionized for separation in the first Ms stage, followed by fragmentation for separation in the second Ms stage.
Translocation breakpoints
locations where two fragments of chromosome(s) are joined subsequent to chromosomal translocation.
Tumour antigens
any antigen produced by the tumour cell, typically in the setting of enriched or specific expression relative to normal tissue(s).
Tumour-associated antigens
antigens whose expression is enriched (but not specific) to cancer cells.
Tumour-specific antigens (Tsas). antigens (molecules capable of promoting an adaptive immune response) expressed by the tumour with minimal to no expression in normal tissue.
Viral-derived cancer antigens
antigens expressed by cancer cells derived from an oncogenic viral origin. . One such explanation for this high false-positive rate is that the current binding prediction tools do not account for other steps involved in MHC peptide processing 182 . A study from Pearson et al. 183 demonstrated that MHC class I associated peptides (MAPs; that is, epitopes) were derived from only 10% of exomic sequences expressed in B lymphocytes, with 41% of protein-coding genes generating no MAPs. Using features of transcripts and proteins associated with efficient MAP production, they generated a logistic regression model to predict whether a gene is capable of MAP generation.
Another approach to improving TSA prediction is to directly predict epitope immunogenicity. As we briefly mentioned above, Neopepsee is a new tool that incorporates a machine-learning algorithm trained on HLA alleles that generate T cell responses to directly predict the immunogenicity of putative neoantigens 44 . Compared with conventional binding affinity metrics, Neopepsee predicted immunogenicity in two external validation datasets with significantly improved sensitivity and specificity, providing evidence in support of direct immunogenicity prediction approaches. Because the Neopepsee algorithm was trained on a broad set of HLA alleles rather than specifically using TSA epitope immunogenicity, biological differences between self-derived neoantigens and the non-self epitopes of the training set may be a limiting factor for algorithmic performance. With an increasingly growing number of clinical trials collecting neoantigen immunogenicity data, future algorithms trained specifically on TSAs may potentially provide even better predictive capabilities.
Mass spectrometry approaches. Apart from computational TSA prediction, mass spectrometry-based peptidomic approaches have been applied for the identification of tumour antigens 184 . The identification of endogenously presented epitopes by mass spectrometry began in the early 1990s 185, 186 . The first peptide antigens were discovered with manual interpretation of tandem mass spectrometry; however, computational methods are now the routine strategy to make comparisons between tandem mass spectrometry and peptide sequences on proteomics databases. While conceptually similar to genomic alignment and sequencing, tandem mass spectrometry sequencing is substantially more error prone and less sensitive. Standard proteomics experiments with complex peptide mixtures from well characterized biological samples are typically only able to identify ~25% of the tandem mass spectra in a proteomics database 187, 188 . In addition to the computational difficulties with sequence identification, peptides can undergo rearrangements in the mass spectrometer, generating sequences that were not present in the original biological sample 189, 190 . Despite these challenges, progress has been made in confirming predicted neoantigens using mass spectrometry. Immunogenomic methods have been used to generate virtual peptidomes from tumour sequencing data, and neoantigens have been identified 191, 192 . A recent study by Laumont et al. 193 used mass spectrometry approaches and observed that approximately 90% of the identified TSAs from two mouse cancer cell lines and seven human primary tumours were derived from noncoding regions, including introns, alternative reading frames, noncoding exons, untranslated region-exon junctions, structural variants and endogenous retroelements. Notably, these noncoding regions are not identified through current exome or transcriptome-based sequencing approaches. This study underscores the potential importance of the alternative TSAs and provides strong evidence for their application in therapy design, importantly demonstrating that classical SNV neoantigens may comprise only a minority of the total TSA repertoire. While these studies have enabled neoantigen discovery on a large scale, the limitations of tandem mass spectrometry alignment and the possibility of unexpected peptide rearrangements mean that suspected neoantigens should be confirmed by direct comparison of the sample's tandem mass spectrum with that of the synthetic peptide 175, 191, 194 .
Conclusion
Conventional SNV neoantigens remain the most well-studied class of TSA, with distinct advantages in terms of ease of prediction, prevalence in a wide cohort of patients and promising preclinical and clinical therapeutic evidence of immunogenicity. While SNV neoantigens will continue to be a driving force for therapeutic vaccine development in the coming years, many groups have broadened the search for other alternative TSAs derived from self-and non-self-antigens. While certain sources of alternative TSAs have been studied for decades (for example, gene fusion proteins and viral antigens), the advent of powerful computational methods for the patient-specific prediction of TSAs has expanded the breadth of targets available for potential clinical applications. Unlike SNV neoantigens, which are largely patient specific in expression 12 , some classes of alternative TSAs are shared among the population (for example, splice variant antigens, gene fusion antigens and hERV antigens), making them ideal for offthe-shelf therapies. Additionally, many of these peptide sequences are highly dissimilar from germline sequences (for example, frameshifts), allowing for potentially greater immunogenicity than SNV neoantigens. Thus, alternative TSAs should play a major role in the future of cancer immunotherapy.
